ENTA Annual CFO
-$78.76 M
+$24.39 M+23.64%
30 September 2024
Summary:
As of January 23, 2025, ENTA annual cash flow from operations is -$78.76 million, with the most recent change of +$24.39 million (+23.64%) on September 30, 2024. During the last 3 years, it has fallen by -$8.77 million (-12.53%). ENTA annual CFO is now -202.73% below its all-time high of $76.67 million, reached on September 30, 2015.ENTA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTA Quarterly CFO
-$10.40 M
+$4.38 M+29.61%
30 September 2024
Summary:
As of January 23, 2025, ENTA quarterly cash flow from operations is -$10.40 million, with the most recent change of +$4.38 million (+29.61%) on September 30, 2024. Over the past year, it has increased by +$11.20 million (+51.86%). ENTA quarterly CFO is now -110.52% below its all-time high of $98.86 million, reached on March 31, 2015.ENTA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTA TTM CFO
-$78.76 M
+$11.20 M+12.45%
30 September 2024
Summary:
As of January 23, 2025, ENTA TTM cash flow from operations is -$78.76 million, with the most recent change of +$11.20 million (+12.45%) on September 30, 2024. Over the past year, it has increased by +$24.39 million (+23.64%). ENTA TTM CFO is now -163.81% below its all-time high of $123.43 million, reached on March 31, 2015.ENTA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +23.6% | +51.9% | +23.6% |
| 3 y3 years | -12.5% | +50.5% | -12.5% |
| 5 y5 years | -210.3% | +50.5% | -12.5% |
ENTA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -12.5% | +23.6% | at high | +70.8% | -15.2% | +26.6% |
| 5 y | 5-year | -210.3% | +23.6% | -170.9% | +70.8% | -247.2% | +26.6% |
| alltime | all time | -202.7% | +23.6% | -110.5% | +70.8% | -163.8% | +26.6% |
Enanta Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | -$78.76 M(-23.6%) | -$10.40 M(-29.6%) | -$78.76 M(-12.5%) |
| June 2024 | - | -$14.78 M(-48.3%) | -$89.97 M(-16.2%) |
| Mar 2024 | - | -$28.60 M(+14.5%) | -$107.32 M(+16.0%) |
| Dec 2023 | - | -$24.99 M(+15.7%) | -$92.50 M(-10.3%) |
| Sept 2023 | -$103.15 M(+21.7%) | -$21.60 M(-32.8%) | -$103.15 M(+6.3%) |
| June 2023 | - | -$32.13 M(+133.1%) | -$97.09 M(+2.7%) |
| Mar 2023 | - | -$13.78 M(-61.3%) | -$94.56 M(-11.8%) |
| Dec 2022 | - | -$35.64 M(+129.4%) | -$107.15 M(+26.4%) |
| Sept 2022 | -$84.78 M(+21.1%) | -$15.53 M(-47.5%) | -$84.78 M(-6.1%) |
| June 2022 | - | -$29.60 M(+12.2%) | -$90.27 M(+0.1%) |
| Mar 2022 | - | -$26.38 M(+98.7%) | -$90.17 M(+31.9%) |
| Dec 2021 | - | -$13.27 M(-36.9%) | -$68.38 M(-2.3%) |
| Sept 2021 | -$70.00 M(-1087.5%) | -$21.02 M(-28.8%) | -$70.00 M(+8.6%) |
| June 2021 | - | -$29.51 M(+544.4%) | -$64.44 M(+63.5%) |
| Mar 2021 | - | -$4.58 M(-69.2%) | -$39.42 M(+95.5%) |
| Dec 2020 | - | -$14.89 M(-3.7%) | -$20.16 M(-384.5%) |
| Sept 2020 | $7.09 M(-90.1%) | -$15.46 M(+244.5%) | $7.09 M(-77.2%) |
| June 2020 | - | -$4.49 M(-130.6%) | $31.09 M(-18.4%) |
| Mar 2020 | - | $14.67 M(+18.7%) | $38.12 M(-28.8%) |
| Dec 2019 | - | $12.36 M(+44.7%) | $53.53 M(-25.1%) |
| Sept 2019 | $71.42 M(+144.4%) | $8.54 M(+237.3%) | $71.42 M(-21.7%) |
| June 2019 | - | $2.53 M(-91.6%) | $91.21 M(-1.6%) |
| Mar 2019 | - | $30.09 M(-0.6%) | $92.73 M(+68.4%) |
| Dec 2018 | - | $30.25 M(+6.7%) | $55.06 M(+88.4%) |
| Sept 2018 | $29.22 M | $28.34 M(+600.1%) | $29.22 M(-49.8%) |
| June 2018 | - | $4.05 M(-153.4%) | $58.19 M(+17.9%) |
| Mar 2018 | - | -$7.58 M(-271.9%) | $49.34 M(-8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | - | $4.41 M(-92.3%) | $53.92 M(+2.4%) |
| Sept 2017 | $52.65 M(+47.0%) | $57.31 M(-1294.9%) | $52.65 M(-876.7%) |
| June 2017 | - | -$4.80 M(+59.8%) | -$6.78 M(+65.5%) |
| Mar 2017 | - | -$3.00 M(-195.5%) | -$4.09 M(-145.7%) |
| Dec 2016 | - | $3.15 M(-247.9%) | $8.96 M(-75.0%) |
| Sept 2016 | $35.81 M(-53.3%) | -$2.13 M(+0.7%) | $35.81 M(+0.7%) |
| June 2016 | - | -$2.11 M(-121.0%) | $35.56 M(+51.5%) |
| Mar 2016 | - | $10.05 M(-66.5%) | $23.47 M(-79.1%) |
| Dec 2015 | - | $29.99 M(-1362.9%) | $112.28 M(+46.4%) |
| Sept 2015 | $76.67 M(+280.0%) | -$2.38 M(-83.3%) | $76.67 M(+3.4%) |
| June 2015 | - | -$14.20 M(-114.4%) | $74.12 M(-40.0%) |
| Mar 2015 | - | $98.86 M(-1862.2%) | $123.43 M(+503.9%) |
| Dec 2014 | - | -$5.61 M(+13.7%) | $20.44 M(+1.3%) |
| Sept 2014 | $20.18 M(+89.4%) | -$4.93 M(-114.0%) | $20.18 M(-10.7%) |
| June 2014 | - | $35.11 M(-950.2%) | $22.61 M(-222.7%) |
| Mar 2014 | - | -$4.13 M(-29.7%) | -$18.43 M(+332.2%) |
| Dec 2013 | - | -$5.87 M(+134.6%) | -$4.26 M(-140.0%) |
| Sept 2013 | $10.65 M(-52.9%) | -$2.50 M(-57.7%) | $10.65 M(-7.0%) |
| June 2013 | - | -$5.92 M(-159.0%) | $11.45 M(-15.5%) |
| Mar 2013 | - | $10.03 M(+10.9%) | $13.55 M(-61.1%) |
| Dec 2012 | - | $9.04 M(-631.4%) | $34.86 M(+54.1%) |
| Sept 2012 | $22.62 M(-5.8%) | -$1.70 M(-55.5%) | $22.62 M(-7.0%) |
| June 2012 | - | -$3.83 M(-112.2%) | $24.32 M(-13.6%) |
| Mar 2012 | - | $31.34 M(-1083.1%) | $28.15 M(-983.1%) |
| Dec 2011 | - | -$3.19 M | -$3.19 M |
| Sept 2011 | $24.02 M(-336.1%) | - | - |
| Sept 2010 | -$10.18 M | - | - |
FAQ
- What is Enanta Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals annual CFO year-on-year change?
- What is Enanta Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly CFO year-on-year change?
- What is Enanta Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals TTM CFO year-on-year change?
What is Enanta Pharmaceuticals annual cash flow from operations?
The current annual CFO of ENTA is -$78.76 M
What is the all time high annual CFO for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high annual cash flow from operations is $76.67 M
What is Enanta Pharmaceuticals annual CFO year-on-year change?
Over the past year, ENTA annual cash flow from operations has changed by +$24.39 M (+23.64%)
What is Enanta Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ENTA is -$10.40 M
What is the all time high quarterly CFO for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high quarterly cash flow from operations is $98.86 M
What is Enanta Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, ENTA quarterly cash flow from operations has changed by +$11.20 M (+51.86%)
What is Enanta Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ENTA is -$78.76 M
What is the all time high TTM CFO for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high TTM cash flow from operations is $123.43 M
What is Enanta Pharmaceuticals TTM CFO year-on-year change?
Over the past year, ENTA TTM cash flow from operations has changed by +$24.39 M (+23.64%)